Loading
A phase 2 trial of Afuresertib run by Laekna Limited, completed.
Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian is a phase 2 interventional study registered as NCT04374630 by Laekna Limited, with 150 participants enrolled, started 2020-07-07, primary completion reached 2023-10-31. Conditions recorded: Platinum-resistant Ovarian Cancer. Interventions recorded: Paclitaxel, Afuresertib.
Shares Afuresertib, Laekna Therapeutics and the tag pipeline.
Shares Afuresertib, Laekna Therapeutics and the tag pipeline.
Shares Afuresertib, Laekna Therapeutics and the tag pipeline.
Shares Afuresertib, Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/